logo-loader

Bitcoin now worth more than Facebook as price smashes US$40,000 barrier

Published: 10:32 08 Jan 2021 EST

Facebook Inc - Bitcoin now worth more than Facebook as price smashes US$40,000 barrier

The cumulative value of Bitcoin has surpassed the market cap of social media giant Facebook Inc (NASDAQ:FB) after the price of the cryptocurrency surged to US$41,111 as of late-afternoon trading in London on Friday.

According to data from platform AssetDash, the total value of all Bitcoins in circulation now stands at US$779.6bn, above Facebook’s market cap of around US$756.6bn.

WATCH: Bitcoin Vs Gold: "Western economic system has become a house of cards"

The rise of Bitcoin also makes it the seventh most valuable asset in the world, while its surge throughout 2020 has also helped the entire crypto market surpass US$1 trillion in value.

However, the cryptocurrency faces a more difficult fight if it wants to crack the top five, with the sixth most valuable entity, Tesla Inc (NASDAQ:TSLA) valued at US$818bn while the fifth place constituent, Google parent Alphabet Inc (NASDAQ:GOOGL), holds a market cap of US$1.2 trillion, US$428bn higher than Bitcoin.

But some analysts also think Bitcoin could run further in the near-term, with OANDA’s Craig Erlam pointing out that it has taken the crypto less than a month to rise to US$40,000 from US$20,000.

However, Erlam warned that the Bitcoin market is “very much in speculative bubble territory” and it is “becoming increasingly likely that it's going to get messy as there's no logic behind what we're seeing”.

“It's pure speculation and [fear of missing out] and that never ends well. I previously said I wouldn't be surprised to see US$50,000 before the end of the month and I'm now thinking that was too conservative. The last US$10,000 move only took four days. It's getting silly now”, he concluded.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

2 hours, 6 minutes ago